ClinicalTrials.Veeva

Menu
A

Arkansas Research Trials | North Little Rock

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Lebrikizumab
Upadacitinib
Rocatinlimab
LY3471851
Remibrutinib
LY3454738
RBX2660
Daxdilimab
ABBV-157
BxC-I17e

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

16 of 31 total trials

A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-SHUTTLE)

The coprimary objectives of the study are to:* evaluate the efficacy of rocatinlimab in combination with topical corticosteroid and/or topical calcin...

Active, not recruiting
Atopic Dermatitis
Drug: Rocatinlimab
Other: Placebo

Systemic lupus erythematosus (SLE) is a systemic chronic autoimmune disease characterized by autoantibody production, inflammation, and tissue damage...

Enrolling
Systemic Lupus Erythematosus
Drug: DS-7011a
Drug: Placebo

This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis...

Enrolling
Hidradenitis Suppurativa
Drug: Placebo
Drug: Eltrekibart

The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to \<18...

Enrolling
Atopic Dermatitis
Eczema
Drug: Placebo
Drug: Lebrikizumab

The main purpose of this study is to describe the efficacy and safety of LY3454738 in adult participants with moderate-to-severe atopic dermatitis (A...

Enrolling
Atopic Dermatitis
Drug: Placebo
Drug: LY3454738
Locations recently updated

Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (...

Enrolling
Hidradenitis Suppurativa
Drug: Upadacitinib
Drug: Placebo
Locations recently updated

Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in ar...

Enrolling
Hidradenitis Suppurativa
Drug: Lutikizumab
Drug: Placebo

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Enrolling
Atopic Dermatitis
Drug: Rocatinlimab
Other: Placebo

The main purpose of this study is to assess the long-term safety and efficacy of lebrikizumab in participants 6 Months to \<18 years of age with mode...

Invitation-only
Atopic Dermatitis
Eczema
Drug: Placebo
Drug: Lebrikizumab

The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy and combination therapy treatment in adolescent subje...

Active, not recruiting
Atopic Dermatitis
Drug: Rocatinlimab
Drug: Placebo

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib
Drug: Placebo for Upadacitinib

The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of a single and multiple SC dose of BxC-I17e in patients wi...

Enrolling
Atopic Dermatitis
Drug: BxC-I17e
Drug: Placebo

The purpose of this extension study is to collect long-term efficacy, safety and tolerability data on remibrutinib in a selected group of participant...

Active, not recruiting
Chronic Spontaneous Urticaria
Drug: LOU064 (blinded)
Drug: Placebo

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

This study is being conducted to evaluate the efficacy and safety of povorcitinib in adults with CSU that is inadequately controlled using SOC treatm...

Enrolling
Angioedema
Hives
Drug: Placebo
Drug: Povorcitinib

A Phase 2, double-blind, randomized, placebo-controlled parallel-group study to evaluate the efficacy and safety of daxdilimab in participants with m...

Active, not recruiting
Discoid Lupus Erythematosus
Drug: Placebo/Daxdilimab
Drug: Daxdilimab

Trial sponsors

Lilly logo
AbbVie logo
Amgen logo
Incyte logo
Nektar Therapeutics logo
Novartis logo
R
B
B
Daiichi Sankyo logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems